March 2013 Editor's Picks: Products from Weiler Engineering and Pharma Technology Inc. (PTI) - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

March 2013 Editor's Picks: Products from Weiler Engineering and Pharma Technology Inc. (PTI)

Equipment and Processing Report

Featured products from Pharmaceutical Technology's monthly newsletter, Equipment & Processing Report

Weiler Engineering
All-electric, blow–fill–seal machine reduces particulate generation

The all-electric model of the Asep-Tech Model 628 blow–fill–seal machine from Weiler Engineering reduces particulate generation compared to the non-electric model, which is beneficial for parenteral applications. The Model 628 has the flexibility to produce sterile, liquid-filled, tamper-evident containers ranging in size from 0.5 mL up to 500 mL, in full-scale production quantities. A two-piece, stepped-base design allows easy maintenance and convenient product discharge. An integral product buffer tank is designed to meet tight fill tolerances. Additional models are available to fulfill higher output and/or larger container size requirements.

Pharma Technology Inc. (PTI)
System combines tablet deduster, metal detector, and tablet tester on one base

The AIO All-In-One Tablet Deduster and Tester System from Pharma Technology Inc. (PTI) includes PTI’s PharmaFlex segmented deduster spiral, a metal detector, and an in-process tablet tester on one machine base. The tablet tester measures weight, hardness, and thickness at regular intervals and feeds data back to the press where it is recorded and can be used to adjust the process. The tester can be positioned on any of the three sides of the deduster’s base and offers cable-free connections for power and data storage.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Equipment and Processing Report,
Click here